Protein Microarray for Monoclonal Immunoglobulin Specificity Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing Monoclonal Gammopathy of Undetermined Significance (MGUS) and multiple myeloma are inadequate, as they lack sensitivity and do not account for the specificity of monoclonal immunoglobulins, leading to limited treatment options and poor prognosis.
Innovation Solution
A protein microarray assay that immobilizes antigens from infectious agents and self-antigens, allowing for the detection of monoclonal immunoglobulin specificity in patients, enabling improved diagnosis, prognosis, and treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (electrophoresis) are used to detect monoclonal immunoglobulins, then the diagnosis can be performed, but the sensitivity is insufficient and specificity information is lost
Solution Approach 1:
The patent segments the diagnostic process by separating the detection of monoclonal immunoglobulins from general protein electrophoresis. It uses specific antigen arrays (infectious agents, self-antigens, tumor-associated antigens) to segment and identify specific immunoglobulin specificities, thereby recovering information that was previously lost in bulk electrophoresis measurements.
Solution Approach 2:
The patent introduces antigen arrays as intermediary elements between the monoclonal immunoglobulins and the detection system. These antigens serve as mediators that specifically bind to monoclonal immunoglobulins, enabling the detection of both presence and specificity. The antigen-antibody interaction acts as the intermediary mechanism that preserves specificity information while enabling sensitive detection.
2Reliability
If monoclonal immunoglobulin production is increased in MGUS and myeloma patients, then the disease progresses, but current methods cannot detect the functional antibody activity or specificity
Solution Approach 1:
The patent replaces the mechanical/electrical separation method (electrophoresis) with a biochemical recognition system based on antigen-antibody specific binding. This substitution enables the detection of functional antibody activity and specificity by utilizing the natural recognition mechanism of the immune system, rather than relying on physical separation properties that lose specificity information.
Solution Approach 2:
The patent creates a universal diagnostic platform that can detect multiple types of monoclonal immunoglobulins with different specificities using a single antigen array system. The platform is multi-functional, capable of detecting infectious agent-specific antibodies, self-antibodies, and tumor-associated antibodies, thereby providing comprehensive monitoring of disease progression and functional antibody activity.
3Adaptability or versatility
If patient stratification is performed using current cytogenetic and genomic methods, then some disease profiles can be identified, but these are often secondary events and treatment responses remain limited
Solution Approach 1:
The patent performs preliminary identification of monoclonal immunoglobulin specificity early in the disease course, before secondary cytogenetic and genomic events occur. By detecting the functional antibody activity and specificity at the earliest stage, the system enables earlier patient stratification and treatment planning, avoiding the time loss associated with waiting for secondary genetic alterations to manifest.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein microarray assay provides a more sensitive and specific method for determining monoclonal immunoglobulin specificity, potentially improving patient stratification, treatment responses, and prognosis in MGUS and multiple myeloma.
Implementation Method 1
A protein microarray assay that immobilizes antigens from infectious agents and self-antigens, allowing for the detection of monoclonal immunoglobulin specificity in patients
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3B
AI summary
The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.